In October 2007, the FDA declared that the labeling for all PDE5 inhibitors, which includes tadalafil, requires a more popular warning of the possible hazard of sudden Listening to decline as the results of publish-marketing stories of short-term deafness related to usage of PDE5 inhibitors.[19]